HomeCompareTKAGY vs MRK

TKAGY vs MRK: Dividend Comparison 2026

TKAGY yields 3.73% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TKAGY wins by $119.6K in total portfolio value
10 years
TKAGY
TKAGY
● Live price
3.73%
Share price
$15.28
Annual div
$0.57
5Y div CAGR
43.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$177.3K
Annual income
$73,169.93
Full TKAGY calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — TKAGY vs MRK

📍 TKAGY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTKAGYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TKAGY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TKAGY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TKAGY
Annual income on $10K today (after 15% tax)
$317.18/yr
After 10yr DRIP, annual income (after tax)
$62,194.44/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, TKAGY beats the other by $53,597.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TKAGY + MRK for your $10,000?

TKAGY: 50%MRK: 50%
100% MRK50/50100% TKAGY
Portfolio after 10yr
$117.5K
Annual income
$41,641.86/yr
Blended yield
35.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TKAGY
No analyst data
Altman Z
1.7
Piotroski
6/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TKAGY buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTKAGYMRK
Forward yield3.73%2.81%
Annual dividend / share$0.57$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR43.5%32.7%
Portfolio after 10y$177.3K$57.7K
Annual income after 10y$73,169.93$10,113.78
Total dividends collected$145.3K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TKAGY vs MRK ($10,000, DRIP)

YearTKAGY PortfolioTKAGY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,235$535.48$11,213$373.04+$22.00TKAGY
2$12,829$806.87$12,667$512.06+$162.00TKAGY
3$14,962$1,235.58$14,439$708.14+$523.00TKAGY
4$17,942$1,932.65$16,640$988.16+$1.3KTKAGY
5$22,307$3,108.13$19,432$1,394.07+$2.9KTKAGY
6$29,050$5,182.25$23,057$1,992.90+$6.0KTKAGY
7$40,135$9,051.16$27,889$2,894.79+$12.2KTKAGY
8$59,715$16,770.47$34,518$4,286.29+$25.2KTKAGY
9$97,359$33,463.62$43,912$6,494.35+$53.4KTKAGY
10$177,344$73,169.93$57,714$10,113.78+$119.6KTKAGY

TKAGY vs MRK: Complete Analysis 2026

TKAGYStock

Telekom Austria AG, together with its subsidiaries, provides fixed-line and mobile communications solutions to individuals, commercial and non-commercial organizations, and other national and international carriers. The company offers fixed-line services, including access, Internet, fixed-to-mobile calls, international traffic, voice value-added, interconnection, call center, television, IPTV, and smart home services, as well as data and ICT solutions; and digital mobile communications services, such as text and multimedia messaging, m-commerce, information, and entertainment services. It also provides end-user terminal equipment; digital products; cloud and Internet of Things services; and mobile payment services. The company provides digital services and communications solutions to approximately 26 million customers. It has operations in Austria, Belarus, Bulgaria, Croatia, North Macedonia, Serbia, and Slovenia. The company is headquartered in Vienna, Austria. Telekom Austria AG is a subsidiary of América Móvil B.V.

Full TKAGY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TKAGY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TKAGY vs SCHDTKAGY vs JEPITKAGY vs OTKAGY vs KOTKAGY vs MAINTKAGY vs JNJTKAGY vs ABBVTKAGY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.